222 related articles for article (PubMed ID: 9672256)
21. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA.
Dixit M; Yang JL; Poirier MC; Price JO; Andrews PA; Arteaga CL
J Natl Cancer Inst; 1997 Mar; 89(5):365-73. PubMed ID: 9060958
[TBL] [Abstract][Full Text] [Related]
22. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
Pomerantz RG; Grandis JR
Semin Oncol; 2004 Dec; 31(6):734-43. PubMed ID: 15599851
[TBL] [Abstract][Full Text] [Related]
23. Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus.
Zaoui K; Bossow S; Grossardt C; Leber MF; Springfeld C; Plinkert PK; Kalle Cv; Ungerechts G
Cancer Gene Ther; 2012 Mar; 19(3):181-91. PubMed ID: 22076043
[TBL] [Abstract][Full Text] [Related]
24. Abrogation of VEGF expression in human head and neck squamous cell carcinoma decreases angiogenic activity in vitro and in vivo.
Riedel F; Götte K; Li M; Hörmann K; Grandis JR
Int J Oncol; 2003 Sep; 23(3):577-83. PubMed ID: 12888890
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR.
Wang D; Su L; Huang D; Zhang H; Shin DM; Chen ZG
Mol Cancer; 2011 Sep; 10():116. PubMed ID: 21939503
[TBL] [Abstract][Full Text] [Related]
26. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
27. Lack of toxicity of EGFR antisense gene therapy.
Zeng Q; Kanter PM; Dhir R; Gooding WE; Huang L; Grandis JR
J Exp Ther Oncol; 2002; 2(3):174-86. PubMed ID: 12415634
[TBL] [Abstract][Full Text] [Related]
28. E1A-mediated suppression of EGFR expression and induction of apoptosis in head and neck squamous carcinoma cell lines.
Flinterman M; Gäken J; Farzaneh F; Tavassoli M
Oncogene; 2003 Apr; 22(13):1965-77. PubMed ID: 12673202
[TBL] [Abstract][Full Text] [Related]
29. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
30. Receptor-mediated delivery of an antisense gene to human brain cancer cells.
Zhang Y; Jeong Lee H; Boado RJ; Pardridge WM
J Gene Med; 2002; 4(2):183-94. PubMed ID: 11933219
[TBL] [Abstract][Full Text] [Related]
31. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Bruzzese F; Leone A; Rocco M; Carbone C; Piro G; Caraglia M; Di Gennaro E; Budillon A
J Cell Physiol; 2011 Sep; 226(9):2378-90. PubMed ID: 21660961
[TBL] [Abstract][Full Text] [Related]
32. [Study on interference therapy induced by epidermal growth factor receptor-antisense cDNA in signal transduction of laryngeal squamous cell carcinoma].
Xian JM; Zhou GY; Liang CY; Liu SX
Hua Xi Kou Qiang Yi Xue Za Zhi; 2007 Dec; 25(6):540-3, 547. PubMed ID: 18306620
[TBL] [Abstract][Full Text] [Related]
33. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
34. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
35. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts.
Stanton P; Richards S; Reeves J; Nikolic M; Edington K; Clark L; Robertson G; Souter D; Mitchell R; Hendler FJ
Br J Cancer; 1994 Sep; 70(3):427-33. PubMed ID: 8080726
[TBL] [Abstract][Full Text] [Related]
36. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
37. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line.
DeFatta RJ; Nathan CO; De Benedetti A
Laryngoscope; 2000 Jun; 110(6):928-33. PubMed ID: 10852506
[TBL] [Abstract][Full Text] [Related]
38. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression, and tumor growth in vivo.
Duffey DC; Chen Z; Dong G; Ondrey FG; Wolf JS; Brown K; Siebenlist U; Van Waes C
Cancer Res; 1999 Jul; 59(14):3468-74. PubMed ID: 10416612
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression.
Yamazaki H; Kijima H; Ohnishi Y; Abe Y; Oshika Y; Tsuchida T; Tokunaga T; Tsugu A; Ueyama Y; Tamaoki N; Nakamura M
J Natl Cancer Inst; 1998 Apr; 90(8):581-7. PubMed ID: 9554440
[TBL] [Abstract][Full Text] [Related]
40. In vitro and in vivo characteristics of human squamous cell carcinoma of the head and neck cells engineered to secrete interleukin-2.
Nagashima S; Reichert TE; Kashii Y; Suminami Y; Chikamatsu K; Whiteside TL
Cancer Gene Ther; 1997; 4(6):366-76. PubMed ID: 9408607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
